Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ginwa Enterprise GroupSHSE:600080 -2.51%46 EV-to-EBIT is 57.48 as of Aug. 19, 2026, which is 25% above its 10-year median of 46.06. GuruFocus rates SHSE:600080 with a GF Score™ of 46/100 and a GF Value™ of ¥7.53 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 683 Drug Manufacturers companies, Ginwa Enterprise Group ranks worse than 86.53% on this metric.
Ginwa Enterprise Group (SHSE:600080) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Ginwa Enterprise Group's Enterprise Value for the quarter that ended in Mar. 2026 was ¥2,913.0 Mil.
Ginwa Enterprise Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥26.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ginwa Enterprise Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginwa Enterprise Group EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ginwa Enterprise Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ginwa Enterprise Group's EV-to-EBIT falls into.
Ginwa Enterprise Group's current Enterprise Value is ¥1,498.3 Mil.
Ginwa Enterprise Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥26.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ginwa Enterprise Group (SHSE:600080) has a EV-to-EBIT of 57.48 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ginwa Enterprise Group and its competitors. This is 25% above median its historical median of 46.06. According to the industry distribution chart, Ginwa Enterprise Group ranks #591 out of 683 companies in the Drug Manufacturers industry, placing it in the top 86.5%.
Is Ginwa Enterprise Group's EV-to-EBIT too high?
Ginwa Enterprise Group's current EV-to-EBIT of 57.48 is 25% above median its 10-year median of 46.06. The Drug Manufacturers industry median EV-to-EBIT is 15.97. Ginwa Enterprise Group's value of 57.48 is 259.9% above this industry median. Based on the distribution chart, Ginwa Enterprise Group ranks #591 out of 683 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ginwa Enterprise Group has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ginwa Enterprise Group's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ginwa Enterprise Group ranks #591 out of 683 companies for EV-to-EBIT. This places Ginwa Enterprise Group in the lower half of its industry. The industry median EV-to-EBIT is 15.97. Ginwa Enterprise Group's value of 57.48 is 259.9% above this benchmark. While the company's 10-year median is 46.06 vs. the industry median of 15.97, Ginwa Enterprise Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.97, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ginwa Enterprise Group's current EV-to-EBIT of 57.48 is 259.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ginwa Enterprise Group and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ginwa Enterprise Group's current EV-to-EBIT is 57.48, which is 25% above median its own 10-year median of 46.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginwa Enterprise Group stock overvalued right now?
Based on GuruFocus' analysis, Ginwa Enterprise Group (SHSE:600080) is currently considered Possible Value Trap. The stock's GF Value™ is ¥7.53, compared to a current price of ¥4.67 — trading 38% below its estimated fair value. The current EV-to-EBIT is 57.48, which is 25% above median its 10-year median of 46.06 and 259.9% above the Drug Manufacturers industry median of 15.97. Ginwa Enterprise Group's overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Ginwa Enterprise Group (SHSE:600080), the current EV-to-EBIT is 57.48 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ginwa Enterprise Group (SHSE:600080) Overvalued in 2026?
Based on GuruFocus' analysis, Ginwa Enterprise Group stock appears to be undervalued.
The current stock price of ¥4.67 is trading 38% below its estimated GF Value™ of ¥7.53.
GuruFocus considers Ginwa Enterprise Group to be Possible Value Trap.
Key valuation signals for SHSE:600080:
EV-to-EBIT: 57.48 (25% above median its 10-year median of 46.06)
GF Value™: ¥7.53 vs. price of ¥4.67 (38% below fair value)
Industry Position: 259.9% above the Drug Manufacturers median (#591 of 683)
No single metric tells the full story. See the SHSE:600080 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ginwa Enterprise Group Inc operates in the pharmaceutical industry. The main business is the research and development, production, and sales of drugs, and the product line covers chemical drugs, Chinese patent medicines, raw materials, and health products. The dosage forms include tablets, capsules, granules, powders, mixtures, oral solutions, syrups, external solutions, and more than 100 varieties and specifications.
46GF Score
Get the complete analysis for SHSE:600080
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600080 has been successfully added to your 
